H.C. Wainwright Downgrades Juniper Pharmaceuticals (JNP) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. APLD
10. LEVI

Go back to H.C. Wainwright Downgrades Juniper Pharmaceuticals (JNP) to Neutral

Juniper Pharmaceuticals Reports Results from Phase 2b Clinical Trial of COL-1077 Lidocaine Vaginal Gel in Gynecologic Procedure Pain

August 17, 2016 5:25 PM EDT

BOSTON, Aug. 17, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that a recently completed Phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077, for the reduction of pain intensity in women undergoing an endometrial biopsy with tenaculum placement did not achieve its primary and secondary endpoints.  The safety and pharmacokinetic (PK) profiles of COL-1077 were consistent with what has been observed in prior clinical trials of the lidocaine bioadhesive vaginal gel.... More